Blood plasma fractionation insinuates the general strategies of disconnecting the distinctive parts of blood plasma, which in this way is a portion of blood got past blood fractionation. The plasma fractionation industry is an area of the Biopharmaceutical business in which the plasma segment of human blood is handled to extricate helpful items. The business is moderately developed, with the center plasma fractionation innovation unaltered. Factors, for example, developing maturing populace, rising rates of draining and insusceptible issue, and developing utilization of immunoglobulin and alpha-1-antitrypsin are the essential development drivers for the worldwide plasma fractionation market.
How Big is The Global Plasma Fractionation Market?
The Global Plasma Fractionation Market is expected to be around US$ 37.90 Billion by 2028 at a CAGR of 6.7% in the given forecast period.
The major driving factors of Global Plasma Fractionation Market are as follows:
The restraining factors of Global Plasma Fractionation Market are as follows:
The Global Plasma Fractionation Market is segmented on the lines of its product, application, end user and regional. Based on product segmentation it covers albumin, immunoglobulin, coagulation factor concentrates, protease inhibitors, other plasma fractionation products. Based on application segmentation it covers neurology, immunology, hematology, haemato-oncology, pulmonology, rheumatology, critical care, others. Based on end user segmentation it covers hospitals and clinics, clinical research laboratories, academic institutes. The Global Plasma Fractionation Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Global Plasma Fractionation Market and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Global Plasma Fractionation Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets on Global Plasma Fractionation Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (Germany), LFB S.A (France), Bio Product Laboratory Ltd. (U.K.), and Sanquin (Netherlands). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Plasma Fractionation Market has been segmented as below:
By Product Analysis:
By Application Analysis:
By End User Analysis:
By Regional Analysis:
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Global Plasma Fractionation Market .
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Plasma Fractionation Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Research Approach
2.1.1 Secondary Sources
2.1.2 Key Data From Secondary Sources
2.1.3 Primary Sources
2.1.4 Key Data From Primary Sources
2.1.5 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
3 Executive Summary
4 Premium Insights
4.1 Market Overview
4.2 Asia-Pacific Plasma Fractionation Market
4.3 Plasma Fractionation Market: Geographic Growth Opportunities
4.4 Plasma Fractionation Market: Geographic Mix
4.5 Plasma Fractionation Market: Developing vs Developed Countries
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.3 Key Market Drivers
5.3.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
5.3.2 Rise in the Aging Population Across the Globe
5.3.3 Growing Prevalence of Respiratory Diseases and Aatd Driving the Uptake of Alpha-1 Antitrypsin
5.3.4 Increase in Plasma Collection
5.4 Key Market Restraints
5.4.1 High Cost and Limited Reimbursements
5.4.2 Stringent Government Regulations
5.4.3 Emergence of Recombinant Alternatives
5.5 Key Market Opportunities
5.5.1 Increasing Number of Hemophilic Patients
5.6 Key Challenges
5.6.1 Pricing Pressure Faced By Prominent Players in the Market
6 Industry Insights
6.1 Introduction
6.2 Key Industry Trends
6.2.1 Focus on Increasing Fractionation CAPACities and Geographical Expansions
6.2.2 New Indications for Plasma Products
6.2.3 Rising Adoption of SCIG
6.2.4 Increasing Number of Fractionator-Owned Plasma Collection Centers
6.2.5 Growing Plasma Products Market in China
6.2.6 Increasing Focus of Plasma Fractionators Towards Manufacturing and Development of Recombinant Factors
6.3 Porter’s Five Forces Analysis
6.3.1 Threat of New Entrants
6.3.2 Threat of Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry
7 Global Plasma Fractionation Market, By Product
7.1 Introduction
7.2 Fractionation Process
7.3 Immunoglobulin
7.3.1 Intravenous Immunoglobulin
7.3.2 Subcutaneous Immunoglobulin
7.3.3 Other Immunoglobulins
7.4 Coagulation Factor Concentrates
7.4.1 Factor VIII
7.4.2 Factor IX
7.4.3 Factor XIII
7.4.4 Prothrombin Complex Concentrates
7.4.5 Von Willebrand Factor (VWF)
7.4.6 Fibrinogen Concentrates
7.5 Albumin
7.6 Protease Inhibitors
7.7 Other Plasma Products
8 Global Plasma Fractionation Market, By Application
8.1 Introduction
8.2 Neurology
8.3 Immunology
8.4 Hematology
8.5 Critical Care
8.6 Pulmonology
8.7 Hemato-Oncology
8.8 Rheumatology
8.9 Other Applications
9 Global Plasma Fractionation Market, By End User
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Clinical Research Laboratories
9.4 Academic Institutes
10 Global Plasma Fractionation Market, By Region
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 Italy
10.3.4 Spain
10.3.5 U.K.
10.3.6 Rest of Europe (RoE)
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia-Pacific (Ro-APAC)
10.5 Rest of the World (RoW)
10.5.1 Latin America
10.5.2 Middle East and Africa
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Expansions
11.3.2 Agreements, Collaborations, and Partnerships
11.3.3 New Product Launches
11.3.4 Acquisitions
The Global Plasma Fractionation Market has been segmented as below:
By Product Analysis:
By Application Analysis:
By End User Analysis:
By Regional Analysis:
SUBSCRIBE TO OUR NEWSLETTERS
